Publications
Export 72 results:
Auteur Title Type [ Année
Filtres: Auteur is Pedro Rosa-Neto [Enlever les filtres]
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.. Exp Gerontol.
.
2018. Identification of [F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging.. J Med Chem. 61(4):1737-1743.
.
2018. In vivo quantification of neurofibrillary tangles with [F]MK-6240.. Alzheimers Res Ther. 10(1):74.
.
2018. .
2018. PET/CT of Dementia.. AJR Am J Roentgenol. 211(2):246-259.
.
2018. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.. JAMA Neurol.
.
2018. Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress.. Brain Struct Funct.
.
2018. Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.. Mol Neurobiol.
.
2018. Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.. Hum Brain Mapp. 39(2):971-984.
.
2018. Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.. J Alzheimers Dis.
.
2018. variant mitigates Alzheimer disease pathophysiology in vivo and postmortem.. Neurol Genet. 4(1):e216.
.
2018. Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.. Alzheimers Dement. 15(7):951-960.
.
2019. Astrocyte Biomarkers in Alzheimer's Disease.. Trends Mol Med.
.
2019. Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.. Nat Commun. 10(1):2240.
.
2019. Constrained instruments and their application to Mendelian randomization with pleiotropy.. Genet Epidemiol.
.
2019. First-in-Human Brain Imaging of [F]TRACK, a PET tracer for Tropomyosin Receptor Kinases.. ACS Chem Neurosci. 10(6):2697-2702.
.
2019. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
.
2019. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.. Alzheimers Dement. 15(6):742-753.
.
2019. No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
.
2019. Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.. Nat Commun. 10(1):4227.
.
2019. Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.. Pharmaceuticals (Basel). 12(1)
.
2019. .
2019. Pages
- « first
- ‹ previous
- 1
- 2
- 3